Does antiretroviral therapy interfere with the treatment of trichomonas vaginalis among HIV+ women?

Sexually Transmitted Diseases

Volumn 40, Issue 6, 2013, Pages 506-507

  Kissinger, Patricia ^a   Adamski, Alys ^a   Clark, Rebecca A ^b   Mena, Leandro ^c   Levison, Judy ^d   Martin, David H ^b  

^a TULANE UNIVERSITY   (United States)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; METRONIDAZOLE; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

CD4 LYMPHOCYTE COUNT; CONCURRENT SEXUAL PARTNERSHIP; CONTROLLED STUDY; DOSE RESPONSE; EDITORIAL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; KENYA; MEDICAL RECORD; PRESCRIPTION; SELF REPORT; TREATMENT OUTCOME; TRICHOMONAS VAGINALIS; TRICHOMONIASIS; VIRUS LOAD;

ANTIPROTOZOAL AGENTS; FEMALE; HIV INFECTIONS; HIV SEROPOSITIVITY; HUMANS; METRONIDAZOLE; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

EID: 84878889842     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e31829335fe     Document Type: Editorial

References (11)

1. Schwebke JR, Desmond RA. A randomized controlled trial of partner notification methods for prevention of trichomoniasis in women. Sex Transm Dis 2010; 37:392-396.
2. Kissinger P, Secor WE, Leichliter JS, et al. Early repeated infections with Trichomonas vaginalis among HIV-positive and HIV-negative women. Clin Infect Dis 2008; 46:994-999.
3. Krashin JW, Koumans EH, Bradshaw-S-dnor AC, et al. Trichomonas vagina lis prevalence, incidence, risk factors and antibiotic-resistance in an adolescent population. Sex Transm Dis 2010; 37:440-444.
4. Tidwell BH, Lushbaugh WB, Laughlin MD, et al. A double-blind placebo-controlled trial of single-dose intravaginal versus singledose oral metronidazole in the treatment of trichomonal vaginitis. J Infect Dis 1994; 170:242-246.
5. Spence MR, Harwell TS, Davies MC, et al. The minimum single oral metronidazole dose for treating trichomoniasis: A randomized, blinded study. Obstet Gynecol 1997; 89:699-703.
6. duBouchet L, Spence MR, Rein MF, et al. Multicenter comparison of clotrimazole vaginal tablets, oral metronidazole, and vaginal suppositories containing sulfanilamide, aminacrine hydrochloride, and allantoin in the treatment of symptomatic trichomoniasis. Sex Transm Dis 1997; 24:156-160.
7. Magnus M, Clark R, Myers L, et al. Trichomonas vaginalis among HIV-infected women: Are immune status or protease inhibitor use associated with subsequent T. vaginalis positivity? Sex Transm Dis 2003; 30:839-843.
8. Niccolai LM, Kopicko JJ, Kassie A, et al. Incidence and predictors of reinfection with Trichomonas vaginalis in HIV-infected women. Sex Transm Dis 2000; 27:284-288.
9. Kissinger P, Mena L, Levison J, et al. A randomized treatment trial: Single versus 7-day dose of metronidazole for the treatment of Trichomonas vaginalis among HIV-infected women. J Acquir Immune Defic Syndr 2010; 55:565-571.
10. Gatski M, Martin DH, Levison J, et al. The influence of bacterial vaginosis on the response to Trichomonas vaginalis treatment among HIV-infected women. Sex Transm Infect 2011; 87:205-208.
11. Balkus JE, Richardson BA, Mochache V, et al. A prospective cohort study comparing the effect of single-dose 2 g metronidazole on trichomonas vaginalis infection in HIV-seropositive versus HIVseronegative women. Sex Transm Dis 2013; 40:499-505.